Currently, there are 68.17M common shares owned by the public and among those 53.34M shares have been available to trade.
The company’s stock has a 5-day price change of -3.32% and -14.67% over the past three months. CRVS shares are trading -34.77% year to date (YTD), with the 12-month market performance up to 60.09% higher. It has a 12-month low price of $1.75 and touched a high of $10.00 over the same period. CRVS has an average intraday trading volume of 1.02 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.58%, -1.72%, and -34.18% respectively.
Institutional ownership of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) shares accounts for 29.56% of the company’s 68.17M shares outstanding.
It has a market capitalization of $269.13M and a beta (3y monthly) value of 0.54. The earnings-per-share (ttm) stands at -$0.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.70% over the week and 7.52% over the month.
Earnings per share for the fiscal year are expected to increase by 55.29%, and -34.50% over the next financial year. EPS should grow at an annualized rate of 16.60% over the next five years, compared to 8.47% over the past 5-year period.
Looking at the support for the CRVS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 02, 2025, with the firm’s price target at $11. Oppenheimer coverage for the Corvus Pharmaceuticals Inc (CRVS) stock in a research note released on August 18, 2023 offered a Outperform rating with a price target of $7. Jefferies was of a view on December 01, 2021 that the stock is Buy, while Cantor Fitzgerald gave the stock Overweight rating on May 27, 2021, issuing a price target of $10. Mizuho on their part issued Neutral rating on February 10, 2021.
